MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results 1 for the year ending December 31 ...
The company based in Lexington County received its inspection report back from federal regulators. Here’s what it showed.
Net cash provided by operating activities (GAAP) was $570 million in the fourth quarter of 2022, an increase of 16%, and $2,144 million for full year 2022, an increase of 6%, compared to the same ...
BERLIN, Germany--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting ...
When it comes to pharma’s reputation at the end of 2022, there’s some good news and some bad news. The bad news is that according to the Harris Poll, pharma’s rep in the U.S. is continuing to drop ...
Even as Novartis CEO Vas Narasimhan, M.D., works through a companywide restructuring, the chief exec saw his pay decline substantially in 2022 thanks to demerits on the company’s shareholder return ...
Bormioli Pharma, a global leader partnering with customers to provide comprehensive packaging solutions for injectable drugs, today announced robust growth in its North American business in 2022, with ...
Adam Steensberg, President and Chief Executive at Zealand Pharma said: "Zealand has achieved key objectives in executing the strategy we announced at the end of March to prioritize investment in R&D ...
Pharmaceutical stocks are an important part of any well-rounded investment portfolio. They offer the potential for both high returns and low risk, making them ideal for investors of all types.
“Royalty Pharma delivered strong performance in 2022,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “We reported impressive growth and deployed substantial capital in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results